Fuchs: 3 new crown vaccines funded by the U.S. government will enter Phase 3 trials

So far, the new coronavirus vaccine has shown promising results in animal and human trials, with some expected to be available this year,media BGR reported. These drugs still need to pass the final stages of clinical trials and prove that they can prevent COVID-19 infection before they can be approved for universal use. But the pace of progress in the new vaccine research is incredible, with some of the vaccines set to enter their final phase of trials this summer. There are now more than 130 vaccine candidates under study worldwide, about 10 of which have entered different human trials. U.S. infectious disease expert Dr. Anthony Fauci has now confirmed that three of the vaccines will be used in a wide range of Phase 3 trials funded by the U.S. government.

Fuchs: 3 new crown vaccines funded by the U.S. government will enter Phase 3 trials

“The new coronavirus vaccine is going very well, and we expect more than one candidate vaccine to enter advanced clinical trials by early summer,” Fauci told CNN. “This is good news for the whole new coronavirus vaccine effort. “

The director of the U.S. National Institute of Allergy and Infectious Diseases (NIAID) said the U.S. government will fund phase 3 of all three selected vaccines. Two of them have been reported in the media in the past: Moderna will take the lead in launching phase 3 trials in July, and a month later AstraZeneca’s Oxford vaccine will also be launched.

The third vaccine comes from a company that has not yet announced any results because it has not even started Phase 1 trials. According to the Wall Street Journal, Johnson and Johnson will begin the first phase of human trials in late July and will move on to phase III, pending the results of the first phase and subsequent regulatory approval.

Surprisingly, Pfizer and BioNTech are not included in the NIAID program. A few weeks ago, the two companies collaborated in Germany and the United States on a phase 1 trial of BioNTech’s vaccine, a gene drug similar to the Moderna concept. Pfizer could begin Phase 3 trials in July, according to a person familiar with the vaccine’s progress. AstraZeneca and Oxford University have announced their own three studies in the UK and elsewhere. Recent reports suggest that there may not be enough patients in the UK, which could slow down phase 3 of the drug.

Each of the three U.S. government-funded vaccine studies will include 30,000 people who will receive experimental drugs or placebos. The study will take part in more than 50 locations, most of them in the United States. Depending on the development of the disease, other countries may also be selected. Researchers will hope to study where the virus continues to spread. This is the only way to ensure that volunteers are exposed to pathogens so they can verify that the drug is effective.

The study will see if the vaccine can block the infection, whether it is safe for participants, and whether it can advance to the standard COVID-19 prevention program. If the drugs pass through these final barriers, they may provide emergency use at some point in the fall or winter. It is also important to note that an independent committee will monitor the safety of these drugs and will compare the performance of these vaccines. The Wall Street Journal says it will also look at whether some drugs are better for specific groups of people. This is in line with the advice of Fucci and other experts, who wrote a paper on how to safely and efficiently develop new coronaviruses quickly.

The focus of this extensive study is not on choosing just one vaccine. Fauci et al. explain that the world needs as many lenses as possible to target, and that more than one candidate vaccine will hopefully prevent COVID-19 infection. The more vaccine options you have, the easier it is to deploy on a large scale in the coming years. Production and distribution logistics have not yet been resolved, but work has begun. AstraZeneca has received hundreds of millions of doses from the UK, US and elsewhere. The U.S. government alone invested $1.2 billion in 300 million doses.